However, pretreatment with BMS-303141 markedly attenuated alanine- and glutamine-induced hyperglycemia (Figures 1A–D), suggesting that ACLY activity contributes to hepatic glucose labeling through amino acid–mediated pathways, likely involving ALT transamination. The gene discussed is ACLY; the disease is Hyperglycemia.